About Sarepta Therapeutics, Inc. - Common Stock (SRPT)
Sarepta Therapeutics is a biotechnology company focused on pioneering innovative gene therapies for the treatment of rare genetic diseases, particularly those affecting muscle disorders. The company is dedicated to developing therapies that can enable patients with conditions like Duchenne Muscular Dystrophy to achieve improved outcomes and quality of life. With a strong emphasis on research and development, Sarepta utilizes advanced techniques such as RNA-targeted therapies and gene editing to combat genetic disorders at their source. Through its work, the company aims to transform the landscape of genetic medicine and provide hope for individuals and families affected by these challenging diseases. Read More
The financial markets are a complex ecosystem, constantly reacting to a myriad of inputs, from macroeconomic data to geopolitical shifts. Among the most closely watched catalysts are the pronouncements of influential Wall Street analysts. These upgrades, downgrades, and price target adjustments often act as immediate market movers, capable of sending
Sarepta Therapeutics Inc. (NASDAQ: SRPT) experienced a dramatic downturn in its stock valuation today, November 4, 2025, following the announcement of disappointing results from a pivotal late-stage clinical trial. The biopharmaceutical company revealed that its Phase 3 ESSENCE study, evaluating the efficacy of its Duchenne muscular dystrophy (DMD) therapies Amondys
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025 and the completion of ESSENCE, its global, Phase 3 randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) compared to placebo in 225 patients, ages 6-13 years old, with Duchenne muscular dystrophy (Duchenne) amenable to exon 45 or 53 skipping.
